BMY Valuation

Bristol-Myers Squibb Co

Add to Watchlist

Advanced Chart

45.980

-0.88(-1.878%)1D

Overview
Forecast
Valuation
Earnings

BMY Relative Valuation

BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMY is overvalued; if below, it's undervalued.

Historical Valuation

Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.10 is considered Undervalued compared with the five-year average of 11.44. The fair price of Bristol-Myers Squibb Co (BMY) is between 65.25 to 82.97 according to relative valuation methord. Compared to the current price of 45.98 USD , Bristol-Myers Squibb Co is Undervalued By 29.53%.

Relative Value

Fair Zone

65.25-82.97

Current Price：45.98

29.53%

Undervalued

7.85

Trailing

Forward

8.15

EV/EBITDA

Bristol-Myers Squibb Co. (BMY) has a current EV/EBITDA of 8.15. The 5-year average EV/EBITDA is 9.97. The thresholds are as follows: Strongly Undervalued below 1.47, Undervalued between 1.47 and 5.72, Fairly Valued between 14.22 and 5.72, Overvalued between 14.22 and 18.47, and Strongly Overvalued above 18.47. The current Forward EV/EBITDA of 8.15 falls within the Historic Trend Line -Fairly Valued range.

8.98

EV/EBIT

Bristol-Myers Squibb Co. (BMY) has a current EV/EBIT of 8.98. The 5-year average EV/EBIT is 10.08. The thresholds are as follows: Strongly Undervalued below 0.80, Undervalued between 0.80 and 5.44, Fairly Valued between 14.72 and 5.44, Overvalued between 14.72 and 19.35, and Strongly Overvalued above 19.35. The current Forward EV/EBIT of 8.98 falls within the Historic Trend Line -Fairly Valued range.

2.10

Bristol-Myers Squibb Co. (BMY) has a current PS of 2.10. The 5-year average PS is 2.83. The thresholds are as follows: Strongly Undervalued below 1.82, Undervalued between 1.82 and 2.32, Fairly Valued between 3.33 and 2.32, Overvalued between 3.33 and 3.84, and Strongly Overvalued above 3.84. The current Forward PS of 2.10 falls within the Undervalued range.

7.96

P/OCF

Bristol-Myers Squibb Co. (BMY) has a current P/OCF of 7.96. The 5-year average P/OCF is 8.36. The thresholds are as follows: Strongly Undervalued below 6.34, Undervalued between 6.34 and 7.35, Fairly Valued between 9.36 and 7.35, Overvalued between 9.36 and 10.37, and Strongly Overvalued above 10.37. The current Forward P/OCF of 7.96 falls within the Historic Trend Line -Fairly Valued range.

6.72

P/FCF

Bristol-Myers Squibb Co. (BMY) has a current P/FCF of 6.72. The 5-year average P/FCF is 8.05. The thresholds are as follows: Strongly Undervalued below 5.55, Undervalued between 5.55 and 6.80, Fairly Valued between 9.29 and 6.80, Overvalued between 9.29 and 10.54, and Strongly Overvalued above 10.54. The current Forward P/FCF of 6.72 falls within the Undervalued range.

Bristol-Myers Squibb Co (BMY) has a current Price-to-Book (P/B) ratio of 5.46. Compared to its 3-year average P/B ratio of 5.06 , the current P/B ratio is approximately 7.89% higher. Relative to its 5-year average P/B ratio of 4.55, the current P/B ratio is about 19.91% higher. Bristol-Myers Squibb Co (BMY) has a Forward Free Cash Flow (FCF) yield of approximately 13.72%. Compared to its 3-year average FCF yield of 10.75%, the current FCF yield is approximately 27.62% lower. Relative to its 5-year average FCF yield of 10.21% , the current FCF yield is about 34.37% lower.

5.46

P/B

Median3y

5.06

Median5y

4.55

13.72

FCF Yield

Median3y

10.75

Median5y

10.21

Competitors Valuation Multiple

The average P/S ratio for BMY's competitors is 4.86, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of 2.10, which is -56.87% above the industry average. Given its robust revenue growth of -5.60%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BMY.N

Bristol-Myers Squibb Co

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

4.35

-3.70%

59.88B

Performance Decomposition

Market capitalization of BMY decreased by 3.32% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 7.79 to 17.46.

The secondary factor is the Revenue Growth, contributed -5.60%to the performance.

Overall, the performance of BMY in the past 1 year is driven by P/E Change. Which is more unsustainable.

-5.60%

11.87B → 11.20B

Revenue Growth

-121.90%

-100.36 → 21.98

Margin Expansion

124.18%

7.79 → 17.46

P/E Change

-3.32%